The burgeoning field of obesity management has witnessed remarkable advancements with the emergence of dual GLP-3 receptor agonists, notably Retatrutide and Trizepatide. These groundbreaking therapies represent a https://matteomhwi330610.wikinstructions.com/1939471/glp_3_receptor_agonists_retatrutide_trizepatide